Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00448864
Status:
TERMINATED
Last Update Posted:
2019-06-25
First Post:
2007-03-16
Brief Title:
Efficacy Study of Recombinant Protein Ecallantide to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve RepairReplacement
Sponsor:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Organization:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-05-01
Start Date Type:
ACTUAL
Primary Completion Date:
2008-07-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2008-08-01
Completion Date Type:
ACTUAL
First Submit Date:
2007-03-16
First Submit QC Date:
March 16 2007
Study First Post Date:
2007-03-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2015-07-08
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-06-17
Last Update Post Date:
2019-06-25
Last Update Post Date Type:
ACTUAL